日本新薬 revised down its full-year earnings forecast for fiscal 2026, reducing revenue to ¥191.0 billion and operating profit to ¥33.0 billion, among other items, from the previous forecast. Revenue recognition was reviewed due to the delay in the CAP-1002 review and arbitration with its partner.
日本新薬 announced a revised downward full-year earnings forecast for fiscal 2026, with revenue of ¥191.0 billion, operating profit of ¥33.0 billion, profit before tax of ¥34.0 billion and net income attributable to owners of the parent of ¥27.0 billion. These figures represent decreases of ¥9.0 billion, ¥5.0 billion, ¥4.6 billion and ¥3.3 billion, respectively, from the previous forecast. Research and development expenses are expected to total ¥42.5 billion, an increase of ¥2.0 billion from the previous forecast.
The main factors behind the downward revision include the postponement of the US regulatory review completion date for CAP-1002, a treatment for Duchenne muscular dystrophy, from 22 August to 22 November. Revenue from the drug was excluded from the current-year forecast because its launch timing is now undetermined. The previous revenue forecast for CAP-1002 was ¥11.4 billion.